Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV3KBE)

• Drug Name: 5-(2-methylpiperazin-1-ylsulfonyl)isoquinoline Drug Info
• Synonyms: 1-(5-Isoquinolinylsulfonyl)-2-methylpiperazine; 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; 84477-87-2; H-7; 5-(2-methylpiperazine-1-sulfonyl)isoquinoline; H 7; H7; Piperazine, 1-(5-isoquinolinylsulfonyl)-2-methyl-; BRN 5482740; MLS000069615; CHEMBL323556; CHEBI:43385; Isoquinoline,5-[(2-methyl-1-piperazinyl)sulfonyl]-,hydrochloride (1:2); 5-[(2-methylpiperazin-1-yl)sulfonyl]isoquinoline; SMR000058749; Isoquinoline-5-sulfonic 2-methyl-1-piperazide; 5-(2-methylpiperazin-1-yl)sulfonylisoquinoline; Piperazine, 1-(5-isoquino

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3542
  ChEBI ID: CHEBI:43385
  CAS Number: CAS 84477-87-2
  TTD Drug ID: DMV3KBE

Molecule-Related Drug Atlas

Drug(s) Targeting cAMP-dependent protein kinase A type I (PRKAR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[4]
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[5]
AdoC(Dpr)2AlaArg6	DM2TWSZ	Discovery agent	N.A.	Investigative	[6]
AdcAhxArg4NH(CH2)6NH2	DMSYMRJ	Discovery agent	N.A.	Investigative	[7]
AdcAhxArg4Lys-PEGOMe	DMQ2C8X	Discovery agent	N.A.	Investigative	[7]
AdoC(GABA)Arg6	DMMWNPT	Discovery agent	N.A.	Investigative	[6]
AdcAhxArg4Lys(biotin)-PEG-OMe	DMZYJHV	Discovery agent	N.A.	Investigative	[7]
AdoC(Aun)Arg6	DMDLHAB	Discovery agent	N.A.	Investigative	[6]
Cyclic Guanosine Monophosphate	DMOU93V	Discovery agent	N.A.	Investigative	[5]
AdoCGlyArg6	DMVQJP0	Discovery agent	N.A.	Investigative	[6]

Drug(s) Affected By Telomerase reverse transcriptase (TERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[8]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[9]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[10]
Selenium	DM25CGV	N. A.	N. A.	Approved	[11]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[12]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[14]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[15]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[16]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[17]

Drug(s) Affected By Transforming growth factor beta-1 proprotein (TGFB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[19]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[20]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[21]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[22]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[23]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[24]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[25]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[26]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[27]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
cAMP-dependent protein kinase A type I (PRKAR1A)	TTNAHEX	KAP0_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Telomerase reverse transcriptase (TERT)	OT085VVA	TERT_HUMAN	Gene/Protein Processing	[2]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Gene/Protein Processing	[3]

References

• [1] Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and... J Biol Chem. 1996 Oct 18;271(42):26157-64.
• [2] Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem Biophys Res Commun. 1997 Dec 29;241(3):730-6. doi: 10.1006/bbrc.1997.7874.
• [3] Transcriptional regulation by transforming growth factor beta of the expression of retinoic acid and retinoid X receptor genes in osteoblastic cells is mediated through AP-1. J Biol Chem. 1996 Dec 6;271(49):31602-6. doi: 10.1074/jbc.271.49.31602.
• [4] Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
• [5] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [6] Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
• [7] Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
• [8] Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) alpha+beta+ transcript in estrogen receptor-positive MCF-7 breast cancer cells. Clin Biochem. 2009 Sep;42(13-14):1358-62. doi: 10.1016/j.clinbiochem.2009.05.017. Epub 2009 Jun 6.
• [9] Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006 Sep-Oct;26(5A):3387-91.
• [10] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [11] Inhibitory effects of selenium on telomerase activity and hTERT expression in cadmium-transformed 16HBE cells. Biomed Environ Sci. 2007 Aug;20(4):307-12.
• [12] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [13] Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. BMC Cancer. 2010 Jul 22;10:390. doi: 10.1186/1471-2407-10-390.
• [14] Analysis of telomerase activity and RNA expression in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid. Pediatr Blood Cancer. 2006 Apr;46(4):506-11. doi: 10.1002/pbc.20392.
• [15] Characterization of the functional and growth properties of long-term cell cultures established from a human somatostatinoma. Endocr Relat Cancer. 2006 Mar;13(1):79-93. doi: 10.1677/erc.1.00988.
• [16] Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4. Med Oncol. 2012 Jun;29(2):1209-16. doi: 10.1007/s12032-011-9946-4. Epub 2011 May 5.
• [17] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [18] Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002 Oct;40(4):625-31.
• [19] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [20] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [21] Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res. 2010 Feb 15;70(4):1314-22. doi: 10.1158/0008-5472.CAN-09-3292. Epub 2010 Feb 9.
• [22] PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells. Antioxid Redox Signal. 2002 Dec;4(6):877-84. doi: 10.1089/152308602762197416.
• [23] Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
• [24] Cytokine abnormalities in a patient with eosinophilic fasciitis. Ann Allergy Asthma Immunol. 2003 Apr;90(4):452-5. doi: 10.1016/S1081-1206(10)61832-7.
• [25] Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br J Pharmacol. 2009 Jun;157(3):362-70. doi: 10.1111/j.1476-5381.2009.00161.x. Epub 2009 Apr 9.
• [26] Enhanced apoptosis and transforming growth factor-beta1 expression in colorectal adenomas and carcinomas after Sulindac therapy. Dis Colon Rectum. 2001 Jul;44(7):1008-15. doi: 10.1007/BF02235490.
• [27] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.